Nature Communications (Jan 2021)
Universal toxin-based selection for precise genome engineering in human cells
- Songyuan Li,
- Nina Akrap,
- Silvia Cerboni,
- Michelle J. Porritt,
- Sandra Wimberger,
- Anders Lundin,
- Carl Möller,
- Mike Firth,
- Euan Gordon,
- Bojana Lazovic,
- Aleksandra Sieńska,
- Luna Simona Pane,
- Matthew A. Coelho,
- Giovanni Ciotta,
- Giovanni Pellegrini,
- Marcella Sini,
- Xiufeng Xu,
- Suman Mitra,
- Mohammad Bohlooly-Y,
- Benjamin J. M. Taylor,
- Grzegorz Sienski,
- Marcello Maresca
Affiliations
- Songyuan Li
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Nina Akrap
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Silvia Cerboni
- Translational Science and Experimental Medicine, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca
- Michelle J. Porritt
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Sandra Wimberger
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Anders Lundin
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Carl Möller
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Mike Firth
- R&D Data Infrastructure & Tools, AstraZeneca
- Euan Gordon
- Discovery Biology SWE, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Bojana Lazovic
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Aleksandra Sieńska
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Luna Simona Pane
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Matthew A. Coelho
- Wellcome Sanger Institute
- Giovanni Ciotta
- Discovery Biology UK, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Giovanni Pellegrini
- CVRM pathology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca
- Marcella Sini
- CVRM pathology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca
- Xiufeng Xu
- Department of Biosciences and Nutrition, Karolinska Institute
- Suman Mitra
- Inserm UMR1277 CNRS UMR9020 – CANTHER, Institut pour la Recherche sur le Cancer de Lille
- Mohammad Bohlooly-Y
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Benjamin J. M. Taylor
- Discovery Biology UK, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Grzegorz Sienski
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- Marcello Maresca
- Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca
- DOI
- https://doi.org/10.1038/s41467-020-20810-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Genome engineering in cell lines or human stem cells often has poor efficiency, limiting the development of research and therapeutic applications. Here, the authors use a toxin-based selection system for precise bi-allelic engineering in cells and in vivo.
